(Total Views: 514)
Posted On: 02/17/2020 7:31:57 PM
Post# of 30070
June 2019
Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation
https://www.amarantus.com/news/press-releases...alchemists
Then, no word on Alchemists Kitchen.
Next thing we read is
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
https://www.amarantus.com/news/press-releases...se-diverse
and in that PR it states
Pursuant to the agreement, upon certain conditions, Emerald intends to initiate a tender offer to acquire all outstanding shares of Amarantus.
Now we see in the Letter to Shareholders
Amarantus intends to evaluate a smoking cessation program, with an initial focus of getting feedback on the hemp smokable products from customers who are actively seeking to reduce, or cease, chronic use of cigarettes and/or e-cigarettes
And
Under the terms of the agreement, Amarantus is issuing 25 million shares to Hempori in exchange for 51% of the outstanding shares of Hempori, and was granted an option to acquire the remaining shares from the existing shareholders until December 31, 2020 for additional common stock of Amarantus, or of a successor entity in the event Amarantus is acquired prior to year-end 2020. Hempori generated over $350,000 from its 2 storefronts in fiscal year 2019.
Plus
Five Key Conclusions from recent Surgeon General report on Tobacco Smoking Cessation:
https://www.amarantus.com/news/press-releases...d-wellness
This isn't even including the newly owned patents.
Bezalel’s Jewelry, Inc. CEO Yuen “Vincent” Mao's
Vending machine
https://www.globenewswire.com/news-release/20...mpany.html
or the
OraPatch with PetVivo Holdings Inc.
The fully dissolving wafer-like invention sticks strongly and comfortably the roof of the mouth, cheeks, or gums. This delivery method provides both a rapid release and greater bioavailability when compared to ingestion. Furthermore, the OraPatch product only uses materials deemed to be Generally Recognized as Safe (“GRAS”) by the United States Food and Drug Administration (the “FDA”).
CBD passes the BBB and can be used via the OraPatch.
ELTOP pass the BBB in pill form, so I believe strongly they are working on a combination patch.
And this is still just a portion of what's taking place.
Far more is happening behind the scenes.
I wonder is anything is "still" happening with AK since there is direct overlap.
Now there's
Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
wholly-owned subsidiary MANF Therapeutics has entered into a material transfer agreement (MTA) with Dyadic International, Inc. (Nasdaq
YAI , or Dyadic) to transfer existing batches of mesencephalic astrocyte-derived neurotrophic factor (MANF) therapeutic protein previously manufactured by third parties in baculovirus and CHO to Dyadic to assist in the evaluation of the potential of Dyadic’s proprietary C1 biologics production platform to manufacture MANF for clinical and commercial use...
C1 biologics production platform to manufacture MANF for clinical and commercial use. C1, based on the fungus Myceliophthora thermophila, is a microorganism which enables the development and large scale manufacture of low-cost biologics, and has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologics, including therapeutic proteins such as MANF.
Plus TODOS and everything going on with that.
Just sitting back waiting to see what's announced next and when.
Aloha
Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation
https://www.amarantus.com/news/press-releases...alchemists
Then, no word on Alchemists Kitchen.
Next thing we read is
Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
https://www.amarantus.com/news/press-releases...se-diverse
and in that PR it states
Pursuant to the agreement, upon certain conditions, Emerald intends to initiate a tender offer to acquire all outstanding shares of Amarantus.
Now we see in the Letter to Shareholders
Amarantus intends to evaluate a smoking cessation program, with an initial focus of getting feedback on the hemp smokable products from customers who are actively seeking to reduce, or cease, chronic use of cigarettes and/or e-cigarettes
And
Under the terms of the agreement, Amarantus is issuing 25 million shares to Hempori in exchange for 51% of the outstanding shares of Hempori, and was granted an option to acquire the remaining shares from the existing shareholders until December 31, 2020 for additional common stock of Amarantus, or of a successor entity in the event Amarantus is acquired prior to year-end 2020. Hempori generated over $350,000 from its 2 storefronts in fiscal year 2019.
Plus
Five Key Conclusions from recent Surgeon General report on Tobacco Smoking Cessation:
https://www.amarantus.com/news/press-releases...d-wellness
This isn't even including the newly owned patents.
Bezalel’s Jewelry, Inc. CEO Yuen “Vincent” Mao's
Vending machine
https://www.globenewswire.com/news-release/20...mpany.html
or the
OraPatch with PetVivo Holdings Inc.
The fully dissolving wafer-like invention sticks strongly and comfortably the roof of the mouth, cheeks, or gums. This delivery method provides both a rapid release and greater bioavailability when compared to ingestion. Furthermore, the OraPatch product only uses materials deemed to be Generally Recognized as Safe (“GRAS”) by the United States Food and Drug Administration (the “FDA”).
CBD passes the BBB and can be used via the OraPatch.
ELTOP pass the BBB in pill form, so I believe strongly they are working on a combination patch.
And this is still just a portion of what's taking place.
Far more is happening behind the scenes.
I wonder is anything is "still" happening with AK since there is direct overlap.
Now there's
Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
wholly-owned subsidiary MANF Therapeutics has entered into a material transfer agreement (MTA) with Dyadic International, Inc. (Nasdaq
YAI , or Dyadic) to transfer existing batches of mesencephalic astrocyte-derived neurotrophic factor (MANF) therapeutic protein previously manufactured by third parties in baculovirus and CHO to Dyadic to assist in the evaluation of the potential of Dyadic’s proprietary C1 biologics production platform to manufacture MANF for clinical and commercial use... C1 biologics production platform to manufacture MANF for clinical and commercial use. C1, based on the fungus Myceliophthora thermophila, is a microorganism which enables the development and large scale manufacture of low-cost biologics, and has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologics, including therapeutic proteins such as MANF.
Plus TODOS and everything going on with that.
Just sitting back waiting to see what's announced next and when.
Aloha
(4)
(0)
